Wall Street PR

Pristine Solutions Prepares for FDA Approval of Tropine 3 Transdermal Patch (PRTN)

Shares of Pristine Solutions (OTC: PRTN) have fallen by a small margin of about 1.1%, or $0.0041 per share, to reach $0.3849 as of September 12, 2012. One of the most actively traded penny stock companies, Pristine Solutions is the flagship company that has a wholly owned subsidiary company, Eaton Scientific Systems, under its wings. The company deals with Tropine 3 and holds all intellectual property as well as global marketing rights for the substance.

New Developmental Plans

Though the company’s recent OTC market activity has been average, its news releases are positive and may generate sufficient interest in the company to bump up its share price. On September 10, 2012, Eaton Scientific Systems announced that it was all set to start development of a new Tropine 3 delivery system through the use of a transdermal patch. Tropine 3 is being reckoned as a wonder drug that uses homatropine to treat hot flashes experienced by menopausal women in various stages of exactly that: menopause.

Tropine 3 is still pending patent and FDA approval but is fast becoming a new ray of hope because it is a non-hormonal treatment method aimed at hot flashes in pre, peri and postmenopausal women. If the patent comes through and the drug receives FDA approval, the company believes that it will be the “world’s first ever available prescription non-hormonal transdermal treatment for hot flash symptoms”.

Plans for FDA Approval

The company is basing the developmental study of its product on the proven fact that estrogen patches are quite popular among women. It believes that this leaves the market open for a transdermal Tropine 3 patch that is designed to reduce hot flash symptoms. The company and its subsidiary, Eaton, have a range of Tropine 3 related products and consider a transdermal patch a highly marketable and unique venture.

Preliminary testing is already underway and there are several clinical studies that have been designed to gain compliance from the FDA for its Tropine 3 patches and treatment options. Necessary protocol has been completed and Phase I/II of the clinical trials will soon be underway.

Stock Movement

Shares of Pristine Solutions are traded in high volumes in the over-the-counter market, and it is currently one of the most actively traded penny stocks. In today’s session, the share price opened at $0.37, with the highest price point being recorded at $0.40 and lowest point being recorded as $0.3530. Nearly 5 million shares of Pristine exchanged hands today.

In comparison, another penny stock, Transax International (OTC: TNSX), has continued to trade between $0.003 and $0.002 in the session. This penny stock has closed at a noticeable $0.0115. A high volume stock, around 36.7 million shares in fact, is being traded by the market in regards to this company. Transax is an information networks solution provider for healthcare professionals and insurance companies.

Lifevantage (OTC: LFVN) has also done reasonably well in the last trading session. The share price opened at $3.43 today and the end-of-day stock price was recorded at $3.2926. The last three trading sessions have seen Lifevantage gain a little more than 10% in value.

These are all penny stocks to watch out for in the OTC market.

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http://www.facebook.com/ben.rouss